Bio-Gene TechnologyASX:BGT Market Cap is A$7.72 Mil as of Jun. 28, 2026. The stock has 2 warning signs investors should review. Among 1,429 Biotechnology companies, Bio-Gene Technology ranks worse than 90.34% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bio-Gene Technology's share price for the quarter that ended in Dec. 2025 was A$0.023. Bio-Gene Technology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 305.06 Mil. Therefore, Bio-Gene Technology's market cap for the quarter that ended in Dec. 2025 was A$7.02 Mil.
Bio-Gene Technology's quarterly market cap
declined
from Dec. 2024 (A$8.66 Mil) to Jun. 2025 (A$4.26 Mil) but then
increased
from Jun. 2025 (A$4.26 Mil) to Dec. 2025 (A$7.02 Mil).
Bio-Gene Technology's annual market cap
declined
from Jun. 2023 (A$13.81 Mil) to Jun. 2024 (A$9.87 Mil) and
declined
from Jun. 2024 (A$9.87 Mil) to Jun. 2025 (A$4.26 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bio-Gene Technology's Enterprise Value for Today is A$6.54 Mil.
Bio-Gene Technology (ASX:BGT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Bio-Gene Technology Market Cap Related Terms
Bio-Gene Technology Market Cap Historical Data
* Premium members only.
The historical data trend for Bio-Gene Technology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BGT vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Bio-Gene Technology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gene Technology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's Market Cap distribution charts can be found below:
* The bar in red indicates where Bio-Gene Technology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Bio-Gene Technology's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Gene Technology (ASX:BGT) has a Market Cap of A$7.72 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bio-Gene Technology and its competitors. According to the industry distribution chart, Bio-Gene Technology ranks #1291 out of 1429 companies in the Biotechnology industry, placing it in the top 90.3%.
Is Bio-Gene Technology's Market Cap too high?
Bio-Gene Technology's current Market Cap is A$7.72 Mil. Based on the distribution chart, Bio-Gene Technology ranks #1291 out of 1429 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Gene Technology's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #1291 out of 1429 companies for Market Cap. This places Bio-Gene Technology in the lower half of its industry. The industry median Market Cap is 112.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bio-Gene Technology and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Gene Technology's current Market Cap is A$7.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Market Cap of A$7.72 Mil. The current Market Cap is A$7.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Market Cap is A$7.72 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BGT has been successfully added to your 